Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Leniolisib Phosphate

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharming Group Gets FDA Complete Response Letter For Joenja
    Pharming Group Gets FDA Complete Response Letter For Joenja

    01 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/01/3229924/0/en/Pharming-Group-receives-Complete-Response-Letter-from-U-S-FDA-for-sNDA-for-Joenja-leniolisib-in-children-aged-4-to-11-years-with-APDS.html

    GLOBENEWSWIRE
    01 Feb 2026
    Share Share
    Pharming Group's Leniolisib For APDS In Children Accepted By FDA
    Pharming Group's Leniolisib For APDS In Children Accepted By FDA

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159182/0/en/Pharming-Group-announces-U-S-FDA-acceptance-and-Priority-Review-of-supplemental-New-Drug-Application-for-leniolisib-in-children-with-APDS-aged-4-to-11-years.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Pharming Group starts Phase II trial of leniolisib for CVID
    Pharming Group starts Phase II trial of leniolisib for CVID

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045939/0/en/Pharming-Group-announces-first-patient-dosed-in-Phase-II-clinical-trial-of-leniolisib-for-common-variable-immunodeficiency-CVID-with-immune-dysregulation.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    Pharming Announces Positive Data in Pediatric Leniolisib Trial
    Pharming Announces Positive Data in Pediatric Leniolisib Trial

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/11/2995071/0/en/Pharming-announces-positive-topline-data-in-pediatric-clinical-trial-of-leniolisib.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    Pharming Group Announces Starts Ph2 Trial Of Leniolisib For PIDs
    Pharming Group Announces Starts Ph2 Trial Of Leniolisib For PIDs

    10 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/10/2960994/0/en/Pharming-Group-announces-start-of-Phase-II-clinical-trial-of-leniolisib-for-primary-immunodeficiencies-PIDs-with-immune-dysregulation.html

    GLOBENEWSWIRE
    10 Oct 2024
    Share Share
    Pharming Gets UK Marketing Authorization For Joenja
    Pharming Gets UK Marketing Authorization For Joenja

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2953485/0/en/Pharming-announces-marketing-authorization-in-the-U-K-for-Joenja-leniolisib.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.